nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—COMT—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.0432	0.0971	CbGpPWpGaD
Methyldopa—DDC—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.0397	0.0894	CbGpPWpGaD
Methyldopa—Myocarditis—Capecitabine—esophageal cancer	0.0281	0.0552	CcSEcCtD
Methyldopa—DDC—Parkinsons Disease Pathway—UCHL1—esophageal cancer	0.0243	0.0547	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—SOX2—esophageal cancer	0.0185	0.0415	CbGpPWpGaD
Methyldopa—COMT—Estrogen metabolism—CYP1B1—esophageal cancer	0.0171	0.0384	CbGpPWpGaD
Methyldopa—VIIth nerve paralysis—Capecitabine—esophageal cancer	0.0167	0.0328	CcSEcCtD
Methyldopa—Joint swelling—Capecitabine—esophageal cancer	0.014	0.0275	CcSEcCtD
Methyldopa—DDC—Tryptophan metabolism—ALDH2—esophageal cancer	0.012	0.027	CbGpPWpGaD
Methyldopa—Pericarditis—Methotrexate—esophageal cancer	0.0118	0.0232	CcSEcCtD
Methyldopa—Infection—Carboplatin—esophageal cancer	0.0113	0.0221	CcSEcCtD
Methyldopa—Liver injury—Cisplatin—esophageal cancer	0.0111	0.0217	CcSEcCtD
Methyldopa—Tenderness—Cisplatin—esophageal cancer	0.0107	0.0209	CcSEcCtD
Methyldopa—Bone marrow depression—Capecitabine—esophageal cancer	0.0102	0.0199	CcSEcCtD
Methyldopa—Hepatocellular injury—Cisplatin—esophageal cancer	0.00932	0.0183	CcSEcCtD
Methyldopa—Aminosalicylic Acid—PTGS1—esophageal cancer	0.0092	0.356	CrCbGaD
Methyldopa—DDC—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00909	0.0204	CbGpPWpGaD
Methyldopa—Body temperature increased—Carboplatin—esophageal cancer	0.00896	0.0176	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.00859	0.0193	CbGpPWpGaD
Methyldopa—DDC—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00855	0.0192	CbGpPWpGaD
Methyldopa—COMT—Phase II conjugation—GSTO1—esophageal cancer	0.00777	0.0175	CbGpPWpGaD
Methyldopa—Bone marrow depression—Methotrexate—esophageal cancer	0.00757	0.0148	CcSEcCtD
Methyldopa—Liver disorder—Methotrexate—esophageal cancer	0.0075	0.0147	CcSEcCtD
Methyldopa—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00749	0.0147	CcSEcCtD
Methyldopa—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00746	0.0146	CcSEcCtD
Methyldopa—Nasal congestion—Cisplatin—esophageal cancer	0.00742	0.0146	CcSEcCtD
Methyldopa—Mesalazine—PTGS1—esophageal cancer	0.00722	0.28	CrCbGaD
Methyldopa—DDC—Circadian rythm related genes—CRTC1—esophageal cancer	0.00702	0.0158	CbGpPWpGaD
Methyldopa—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—GNG7—esophageal cancer	0.00672	0.0151	CbGpPWpGaD
Methyldopa—Colitis—Capecitabine—esophageal cancer	0.00659	0.0129	CcSEcCtD
Methyldopa—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00618	0.0121	CcSEcCtD
Methyldopa—Breast disorder—Cisplatin—esophageal cancer	0.00611	0.012	CcSEcCtD
Methyldopa—COMT—Phase II conjugation—GSTT1—esophageal cancer	0.00603	0.0136	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—ADH7—esophageal cancer	0.006	0.0135	CbGpPWpGaD
Methyldopa—Pancreatitis—Cisplatin—esophageal cancer	0.00573	0.0112	CcSEcCtD
Methyldopa—Pancytopenia—Cisplatin—esophageal cancer	0.00555	0.0109	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00554	0.0125	CbGpPWpGaD
Methyldopa—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00552	0.0108	CcSEcCtD
Methyldopa—Libido decreased—Capecitabine—esophageal cancer	0.00538	0.0105	CcSEcCtD
Methyldopa—COMT—Biological oxidations—ADH1B—esophageal cancer	0.00526	0.0118	CbGpPWpGaD
Methyldopa—Aminosalicylic Acid—PTGS2—esophageal cancer	0.00526	0.204	CrCbGaD
Methyldopa—Vasculitis—Methotrexate—esophageal cancer	0.00524	0.0103	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.00511	0.0115	CbGpPWpGaD
Methyldopa—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00495	0.0097	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.00494	0.0111	CbGpPWpGaD
Methyldopa—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00493	0.00966	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP26A1—esophageal cancer	0.00489	0.011	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00482	0.0109	CbGpPWpGaD
Methyldopa—Bradycardia—Cisplatin—esophageal cancer	0.00476	0.00934	CcSEcCtD
Methyldopa—Liver function test abnormal—Capecitabine—esophageal cancer	0.0046	0.00902	CcSEcCtD
Methyldopa—Connective tissue disorder—Cisplatin—esophageal cancer	0.0046	0.00901	CcSEcCtD
Methyldopa—ADRA2A—G alpha (z) signalling events—GNG7—esophageal cancer	0.0046	0.0103	CbGpPWpGaD
Methyldopa—Gynaecomastia—Methotrexate—esophageal cancer	0.00457	0.00897	CcSEcCtD
Methyldopa—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00455	0.00893	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTO1—esophageal cancer	0.00455	0.0102	CbGpPWpGaD
Methyldopa—Breast disorder—Capecitabine—esophageal cancer	0.00451	0.00883	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00449	0.0088	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—GSTO1—esophageal cancer	0.00449	0.0101	CbGpPWpGaD
Methyldopa—Cardiac disorder—Cisplatin—esophageal cancer	0.00434	0.00851	CcSEcCtD
Methyldopa—Abdominal distension—Capecitabine—esophageal cancer	0.00434	0.00851	CcSEcCtD
Methyldopa—Mediastinal disorder—Cisplatin—esophageal cancer	0.00422	0.00827	CcSEcCtD
Methyldopa—Angina pectoris—Capecitabine—esophageal cancer	0.0042	0.00823	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—esophageal cancer	0.00413	0.16	CrCbGaD
Methyldopa—Pancytopenia—Capecitabine—esophageal cancer	0.00409	0.00802	CcSEcCtD
Methyldopa—Flatulence—Cisplatin—esophageal cancer	0.00401	0.00787	CcSEcCtD
Methyldopa—Weight increased—Capecitabine—esophageal cancer	0.00392	0.00769	CcSEcCtD
Methyldopa—Infestation NOS—Capecitabine—esophageal cancer	0.00384	0.00753	CcSEcCtD
Methyldopa—Infestation—Capecitabine—esophageal cancer	0.00384	0.00753	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00384	0.00863	CbGpPWpGaD
Methyldopa—Jaundice—Capecitabine—esophageal cancer	0.00374	0.00734	CcSEcCtD
Methyldopa—COMT—Biological oxidations—ALDH2—esophageal cancer	0.00371	0.00834	CbGpPWpGaD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00367	0.00826	CbGpPWpGaD
Methyldopa—Leukopenia—Cisplatin—esophageal cancer	0.00365	0.00715	CcSEcCtD
Methyldopa—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00363	0.00712	CcSEcCtD
Methyldopa—Agranulocytosis—Capecitabine—esophageal cancer	0.00359	0.00703	CcSEcCtD
Methyldopa—COMT—Biological oxidations—GSTT1—esophageal cancer	0.00353	0.00793	CbGpPWpGaD
Methyldopa—Bradycardia—Capecitabine—esophageal cancer	0.00351	0.00688	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00351	0.00789	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—CYP2A6—esophageal cancer	0.00349	0.00784	CbGpPWpGaD
Methyldopa—Myalgia—Cisplatin—esophageal cancer	0.00347	0.0068	CcSEcCtD
Methyldopa—Hepatitis—Capecitabine—esophageal cancer	0.00345	0.00676	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00344	0.00675	CcSEcCtD
Methyldopa—Liver function test abnormal—Methotrexate—esophageal cancer	0.00343	0.00672	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—PSME1—esophageal cancer	0.00342	0.00768	CbGpPWpGaD
Methyldopa—DDC—Amino acid and derivative metabolism—PSME2—esophageal cancer	0.00342	0.00768	CbGpPWpGaD
Methyldopa—Connective tissue disorder—Capecitabine—esophageal cancer	0.00339	0.00665	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00336	0.00756	CbGpPWpGaD
Methyldopa—Breast disorder—Methotrexate—esophageal cancer	0.00335	0.00658	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00334	0.00655	CcSEcCtD
Methyldopa—Oedema—Cisplatin—esophageal cancer	0.00332	0.00652	CcSEcCtD
Methyldopa—COMT—Biological oxidations—PTGS1—esophageal cancer	0.0033	0.00743	CbGpPWpGaD
Methyldopa—Infection—Cisplatin—esophageal cancer	0.0033	0.00647	CcSEcCtD
Methyldopa—COMT—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00329	0.00739	CbGpPWpGaD
Methyldopa—Nervous system disorder—Cisplatin—esophageal cancer	0.00326	0.00639	CcSEcCtD
Methyldopa—Thrombocytopenia—Cisplatin—esophageal cancer	0.00325	0.00638	CcSEcCtD
Methyldopa—Skin disorder—Cisplatin—esophageal cancer	0.00323	0.00633	CcSEcCtD
Methyldopa—Cardiac disorder—Capecitabine—esophageal cancer	0.0032	0.00628	CcSEcCtD
Methyldopa—Eosinophilia—Methotrexate—esophageal cancer	0.00318	0.00623	CcSEcCtD
Methyldopa—Pancreatitis—Methotrexate—esophageal cancer	0.00314	0.00617	CcSEcCtD
Methyldopa—Angiopathy—Capecitabine—esophageal cancer	0.00313	0.00614	CcSEcCtD
Methyldopa—Mediastinal disorder—Capecitabine—esophageal cancer	0.00311	0.00609	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—GHRL—esophageal cancer	0.00305	0.00687	CbGpPWpGaD
Methyldopa—Pancytopenia—Methotrexate—esophageal cancer	0.00305	0.00597	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00303	0.00594	CcSEcCtD
Methyldopa—Mental disorder—Capecitabine—esophageal cancer	0.00302	0.00592	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—GNG7—esophageal cancer	0.00299	0.00673	CbGpPWpGaD
Methyldopa—Paraesthesia—Cisplatin—esophageal cancer	0.00298	0.00585	CcSEcCtD
Methyldopa—Flatulence—Capecitabine—esophageal cancer	0.00296	0.0058	CcSEcCtD
Methyldopa—Erectile dysfunction—Methotrexate—esophageal cancer	0.00295	0.00579	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00287	0.00563	CcSEcCtD
Methyldopa—Infestation—Methotrexate—esophageal cancer	0.00286	0.00561	CcSEcCtD
Methyldopa—Infestation NOS—Methotrexate—esophageal cancer	0.00286	0.00561	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP1B1—esophageal cancer	0.00281	0.00632	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00277	0.00623	CbGpPWpGaD
Methyldopa—Hepatobiliary disease—Methotrexate—esophageal cancer	0.0027	0.0053	CcSEcCtD
Methyldopa—Leukopenia—Capecitabine—esophageal cancer	0.00269	0.00527	CcSEcCtD
Methyldopa—COMT—Neuronal System—GNG7—esophageal cancer	0.00269	0.00604	CbGpPWpGaD
Methyldopa—Agranulocytosis—Methotrexate—esophageal cancer	0.00267	0.00523	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP19A1—esophageal cancer	0.00264	0.00594	CbGpPWpGaD
Methyldopa—Body temperature increased—Cisplatin—esophageal cancer	0.00263	0.00515	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00261	0.00586	CbGpPWpGaD
Methyldopa—Hepatitis—Methotrexate—esophageal cancer	0.00257	0.00503	CcSEcCtD
Methyldopa—Arthralgia—Capecitabine—esophageal cancer	0.00256	0.00501	CcSEcCtD
Methyldopa—Myalgia—Capecitabine—esophageal cancer	0.00256	0.00501	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00254	0.00498	CcSEcCtD
Methyldopa—COMT—Neuronal System—ALDH2—esophageal cancer	0.00252	0.00566	CbGpPWpGaD
Methyldopa—Oedema—Capecitabine—esophageal cancer	0.00245	0.0048	CcSEcCtD
Methyldopa—Hypersensitivity—Cisplatin—esophageal cancer	0.00245	0.0048	CcSEcCtD
Methyldopa—Infection—Capecitabine—esophageal cancer	0.00243	0.00477	CcSEcCtD
Methyldopa—Nervous system disorder—Capecitabine—esophageal cancer	0.0024	0.00471	CcSEcCtD
Methyldopa—Thrombocytopenia—Capecitabine—esophageal cancer	0.0024	0.0047	CcSEcCtD
Methyldopa—Asthenia—Cisplatin—esophageal cancer	0.00238	0.00468	CcSEcCtD
Methyldopa—Cardiac disorder—Methotrexate—esophageal cancer	0.00238	0.00467	CcSEcCtD
Methyldopa—Skin disorder—Capecitabine—esophageal cancer	0.00238	0.00467	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—GNG7—esophageal cancer	0.00235	0.00529	CbGpPWpGaD
Methyldopa—Angiopathy—Methotrexate—esophageal cancer	0.00233	0.00457	CcSEcCtD
Methyldopa—Mediastinal disorder—Methotrexate—esophageal cancer	0.00231	0.00454	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.00231	0.00519	CbGpPWpGaD
Methyldopa—Diarrhoea—Cisplatin—esophageal cancer	0.00227	0.00446	CcSEcCtD
Methyldopa—SLC15A1—epithelium—esophageal cancer	0.00226	0.115	CbGeAlD
Methyldopa—Mental disorder—Methotrexate—esophageal cancer	0.00225	0.00441	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00223	0.00438	CcSEcCtD
Methyldopa—Paraesthesia—Capecitabine—esophageal cancer	0.0022	0.00431	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00212	0.00415	CcSEcCtD
Methyldopa—Vomiting—Cisplatin—esophageal cancer	0.00211	0.00414	CcSEcCtD
Methyldopa—Rash—Cisplatin—esophageal cancer	0.0021	0.00411	CcSEcCtD
Methyldopa—Constipation—Capecitabine—esophageal cancer	0.0021	0.00411	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00209	0.00471	CbGpPWpGaD
Methyldopa—Dermatitis—Cisplatin—esophageal cancer	0.00209	0.00411	CcSEcCtD
Methyldopa—Leukopenia—Methotrexate—esophageal cancer	0.002	0.00392	CcSEcCtD
Methyldopa—COMT—bronchus—esophageal cancer	0.00198	0.101	CbGeAlD
Methyldopa—Nausea—Cisplatin—esophageal cancer	0.00197	0.00387	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00197	0.00443	CbGpPWpGaD
Methyldopa—Body temperature increased—Capecitabine—esophageal cancer	0.00194	0.0038	CcSEcCtD
Methyldopa—COMT—smooth muscle tissue—esophageal cancer	0.00193	0.0988	CbGeAlD
Methyldopa—DDC—lung—esophageal cancer	0.00193	0.0985	CbGeAlD
Methyldopa—Arthralgia—Methotrexate—esophageal cancer	0.0019	0.00373	CcSEcCtD
Methyldopa—Myalgia—Methotrexate—esophageal cancer	0.0019	0.00373	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.00189	0.00371	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.00188	0.00424	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00187	0.0042	CbGpPWpGaD
Methyldopa—Infection—Methotrexate—esophageal cancer	0.00181	0.00355	CcSEcCtD
Methyldopa—Hypersensitivity—Capecitabine—esophageal cancer	0.00181	0.00354	CcSEcCtD
Methyldopa—Nervous system disorder—Methotrexate—esophageal cancer	0.00179	0.00351	CcSEcCtD
Methyldopa—Thrombocytopenia—Methotrexate—esophageal cancer	0.00179	0.0035	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00178	0.00401	CbGpPWpGaD
Methyldopa—COMT—trachea—esophageal cancer	0.00177	0.0906	CbGeAlD
Methyldopa—Skin disorder—Methotrexate—esophageal cancer	0.00177	0.00347	CcSEcCtD
Methyldopa—Asthenia—Capecitabine—esophageal cancer	0.00176	0.00345	CcSEcCtD
Methyldopa—SLC15A1—digestive system—esophageal cancer	0.00172	0.0877	CbGeAlD
Methyldopa—DDC—Circadian rythm related genes—NOS2—esophageal cancer	0.00171	0.00385	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00171	0.00384	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00171	0.00384	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PFN1—esophageal cancer	0.00168	0.00379	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CAPZA1—esophageal cancer	0.00168	0.00378	CbGpPWpGaD
Methyldopa—Diarrhoea—Capecitabine—esophageal cancer	0.00168	0.00329	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.00166	0.00326	CcSEcCtD
Methyldopa—Paraesthesia—Methotrexate—esophageal cancer	0.00164	0.00321	CcSEcCtD
Methyldopa—Dizziness—Capecitabine—esophageal cancer	0.00162	0.00318	CcSEcCtD
Methyldopa—DDC—Metabolism—SLC52A3—esophageal cancer	0.0016	0.0036	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BLVRB—esophageal cancer	0.0016	0.0036	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00157	0.00309	CcSEcCtD
Methyldopa—Vomiting—Capecitabine—esophageal cancer	0.00156	0.00305	CcSEcCtD
Methyldopa—Rash—Capecitabine—esophageal cancer	0.00154	0.00303	CcSEcCtD
Methyldopa—Dermatitis—Capecitabine—esophageal cancer	0.00154	0.00303	CcSEcCtD
Methyldopa—Headache—Capecitabine—esophageal cancer	0.00153	0.00301	CcSEcCtD
Methyldopa—COMT—digestive system—esophageal cancer	0.00153	0.078	CbGeAlD
Methyldopa—Nausea—Capecitabine—esophageal cancer	0.00146	0.00285	CcSEcCtD
Methyldopa—Body temperature increased—Methotrexate—esophageal cancer	0.00144	0.00283	CcSEcCtD
Methyldopa—COMT—Metabolism—BLVRB—esophageal cancer	0.00142	0.00319	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC52A3—esophageal cancer	0.00142	0.00319	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—CFL1—esophageal cancer	0.00136	0.00307	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CA1—esophageal cancer	0.00136	0.00306	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC10A2—esophageal cancer	0.00136	0.00306	CbGpPWpGaD
Methyldopa—Hypersensitivity—Methotrexate—esophageal cancer	0.00134	0.00263	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00132	0.00298	CbGpPWpGaD
Methyldopa—DDC—lymph node—esophageal cancer	0.00132	0.0674	CbGeAlD
Methyldopa—Asthenia—Methotrexate—esophageal cancer	0.00131	0.00257	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00129	0.00291	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—GNG7—esophageal cancer	0.00129	0.00289	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.00128	0.00288	CbGpPWpGaD
Methyldopa—COMT—lung—esophageal cancer	0.00127	0.0651	CbGeAlD
Methyldopa—Diarrhoea—Methotrexate—esophageal cancer	0.00125	0.00245	CcSEcCtD
Methyldopa—DDC—Metabolism—CA2—esophageal cancer	0.00124	0.0028	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—GNG7—esophageal cancer	0.00122	0.00276	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CA1—esophageal cancer	0.00121	0.00271	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC10A2—esophageal cancer	0.00121	0.00271	CbGpPWpGaD
Methyldopa—Dizziness—Methotrexate—esophageal cancer	0.00121	0.00237	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00117	0.00264	CbGpPWpGaD
Methyldopa—Vomiting—Methotrexate—esophageal cancer	0.00116	0.00227	CcSEcCtD
Methyldopa—DDC—Metabolism—PLCE1—esophageal cancer	0.00116	0.0026	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ADH7—esophageal cancer	0.00116	0.0026	CbGpPWpGaD
Methyldopa—Rash—Methotrexate—esophageal cancer	0.00115	0.00226	CcSEcCtD
Methyldopa—Dermatitis—Methotrexate—esophageal cancer	0.00115	0.00225	CcSEcCtD
Methyldopa—Headache—Methotrexate—esophageal cancer	0.00114	0.00224	CcSEcCtD
Methyldopa—ADRA2A—Hemostasis—ATP1B2—esophageal cancer	0.00111	0.0025	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CA2—esophageal cancer	0.0011	0.00248	CbGpPWpGaD
Methyldopa—Nausea—Methotrexate—esophageal cancer	0.00108	0.00212	CcSEcCtD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00108	0.00243	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	0.00105	0.00236	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—EP300—esophageal cancer	0.00105	0.00236	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ADH7—esophageal cancer	0.00103	0.00231	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PLCE1—esophageal cancer	0.00103	0.00231	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ADH1B—esophageal cancer	0.00101	0.00228	CbGpPWpGaD
Methyldopa—ADRA2A—bronchus—esophageal cancer	0.00101	0.0514	CbGeAlD
Methyldopa—ADRA2A—Hemostasis—DOCK2—esophageal cancer	0.00101	0.00226	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—ANXA1—esophageal cancer	0.001	0.00226	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—SST—esophageal cancer	0.000976	0.0022	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TYMP—esophageal cancer	0.000969	0.00218	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP26A1—esophageal cancer	0.000942	0.00212	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALOX15—esophageal cancer	0.000918	0.00207	CbGpPWpGaD
Methyldopa—ADRA2A—trachea—esophageal cancer	0.000903	0.0462	CbGeAlD
Methyldopa—COMT—Metabolism—ADH1B—esophageal cancer	0.0009	0.00202	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TPI1—esophageal cancer	0.000876	0.00197	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTO1—esophageal cancer	0.000876	0.00197	CbGpPWpGaD
Methyldopa—COMT—lymph node—esophageal cancer	0.000872	0.0445	CbGeAlD
Methyldopa—ADRA2A—Hemostasis—PFN1—esophageal cancer	0.000868	0.00195	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TYMP—esophageal cancer	0.00086	0.00193	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.000858	0.00193	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALDOB—esophageal cancer	0.00084	0.00189	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP26A1—esophageal cancer	0.000837	0.00188	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALOX15—esophageal cancer	0.000815	0.00183	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GAPDH—esophageal cancer	0.000808	0.00182	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CRABP1—esophageal cancer	0.000801	0.0018	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000798	0.00179	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTO1—esophageal cancer	0.000778	0.00175	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TPI1—esophageal cancer	0.000778	0.00175	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000776	0.00175	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GNG7—esophageal cancer	0.000762	0.00171	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000756	0.0017	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—esophageal cancer	0.000749	0.00169	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000748	0.00168	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALDOB—esophageal cancer	0.000746	0.00168	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GNG7—esophageal cancer	0.000742	0.00167	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GAPDH—esophageal cancer	0.000718	0.00161	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000715	0.00161	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ALDH2—esophageal cancer	0.000714	0.00161	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CRABP1—esophageal cancer	0.000711	0.0016	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CFL1—esophageal cancer	0.000704	0.00158	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000687	0.00154	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTT1—esophageal cancer	0.000679	0.00153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000679	0.00153	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GNG7—esophageal cancer	0.000677	0.00152	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP2A6—esophageal cancer	0.000671	0.00151	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—GNG7—esophageal cancer	0.000663	0.00149	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL2—esophageal cancer	0.000653	0.00147	CbGpPWpGaD
Methyldopa—ADRA2A—lung—esophageal cancer	0.000649	0.0332	CbGeAlD
Methyldopa—DDC—Metabolism—PTGS1—esophageal cancer	0.000636	0.00143	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ENO1—esophageal cancer	0.000636	0.00143	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALDH2—esophageal cancer	0.000634	0.00143	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PSME2—esophageal cancer	0.000627	0.00141	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PSME1—esophageal cancer	0.000627	0.00141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GDI2—esophageal cancer	0.000622	0.0014	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—ANXA1—esophageal cancer	0.000607	0.00137	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTT1—esophageal cancer	0.000603	0.00136	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP2A6—esophageal cancer	0.000596	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—SST—esophageal cancer	0.000591	0.00133	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—GHRL—esophageal cancer	0.000576	0.0013	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ENO1—esophageal cancer	0.000565	0.00127	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS1—esophageal cancer	0.000565	0.00127	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BLVRB—esophageal cancer	0.000564	0.00127	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC52A3—esophageal cancer	0.000564	0.00127	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PSME1—esophageal cancer	0.000557	0.00125	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PSME2—esophageal cancer	0.000557	0.00125	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP1B1—esophageal cancer	0.000541	0.00122	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HSPA5—esophageal cancer	0.000541	0.00122	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP19A1—esophageal cancer	0.000509	0.00114	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000482	0.00108	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP1B1—esophageal cancer	0.00048	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CA1—esophageal cancer	0.00048	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC10A2—esophageal cancer	0.00048	0.00108	CbGpPWpGaD
Methyldopa—DDC—Metabolism—HMOX1—esophageal cancer	0.000464	0.00104	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000459	0.00103	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP19A1—esophageal cancer	0.000452	0.00102	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KMT2D—esophageal cancer	0.00045	0.00101	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—esophageal cancer	0.000446	0.001	CbGpPWpGaD
Methyldopa—ADRA2A—lymph node—esophageal cancer	0.000444	0.0227	CbGeAlD
Methyldopa—ADRA2A—GPCR downstream signaling—PDE4D—esophageal cancer	0.000441	0.000991	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CA2—esophageal cancer	0.000439	0.000987	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKAP13—esophageal cancer	0.000438	0.000984	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNG7—esophageal cancer	0.000419	0.000943	CbGpPWpGaD
Methyldopa—COMT—Metabolism—HMOX1—esophageal cancer	0.000412	0.000927	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADH7—esophageal cancer	0.000408	0.000917	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PLCE1—esophageal cancer	0.000408	0.000917	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000401	0.000902	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ABL1—esophageal cancer	0.0004	0.000901	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PDE4D—esophageal cancer	0.0004	0.0009	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—esophageal cancer	0.000396	0.00089	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNG7—esophageal cancer	0.000381	0.000856	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000369	0.000831	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—WWOX—esophageal cancer	0.000367	0.000825	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADH1B—esophageal cancer	0.000358	0.000804	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FKBP1A—esophageal cancer	0.000349	0.000785	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000343	0.000772	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TYMP—esophageal cancer	0.000342	0.000769	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—WIF1—esophageal cancer	0.000341	0.000767	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL2—esophageal cancer	0.000335	0.000754	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—SST—esophageal cancer	0.000334	0.000751	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP26A1—esophageal cancer	0.000332	0.000748	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GHRL—esophageal cancer	0.000325	0.000732	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALOX15—esophageal cancer	0.000324	0.000729	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000315	0.000708	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ANXA1—esophageal cancer	0.000312	0.000701	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TPI1—esophageal cancer	0.000309	0.000695	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTO1—esophageal cancer	0.000309	0.000695	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—SST—esophageal cancer	0.000303	0.000682	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CREBBP—esophageal cancer	0.000298	0.00067	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDOB—esophageal cancer	0.000296	0.000667	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GHRL—esophageal cancer	0.000296	0.000665	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PFN1—esophageal cancer	0.000294	0.000662	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS2—esophageal cancer	0.000289	0.000649	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GAPDH—esophageal cancer	0.000285	0.000642	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CRABP1—esophageal cancer	0.000283	0.000636	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNG7—esophageal cancer	0.000269	0.000605	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NOS3—esophageal cancer	0.000267	0.0006	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CREBBP—esophageal cancer	0.000264	0.000595	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ELMO1—esophageal cancer	0.000264	0.000595	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CREBBP—esophageal cancer	0.000259	0.000583	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKAP13—esophageal cancer	0.000258	0.000581	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	0.000253	0.00057	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALDH2—esophageal cancer	0.000252	0.000567	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—esophageal cancer	0.000244	0.000549	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—esophageal cancer	0.00024	0.000539	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000239	0.000536	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2A6—esophageal cancer	0.000237	0.000533	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—esophageal cancer	0.000237	0.000533	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDE4D—esophageal cancer	0.000236	0.000532	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—esophageal cancer	0.000232	0.000522	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNG7—esophageal cancer	0.000225	0.000506	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO1—esophageal cancer	0.000225	0.000505	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS1—esophageal cancer	0.000225	0.000505	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSME1—esophageal cancer	0.000221	0.000498	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSME2—esophageal cancer	0.000221	0.000498	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—esophageal cancer	0.000217	0.000487	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—XIAP—esophageal cancer	0.000211	0.000474	CbGpPWpGaD
Methyldopa—DDC—Metabolism—EP300—esophageal cancer	0.000203	0.000456	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CTNNA1—esophageal cancer	0.000199	0.000448	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL2—esophageal cancer	0.000198	0.000446	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1B1—esophageal cancer	0.000191	0.000429	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSME2—esophageal cancer	0.000185	0.000416	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSME1—esophageal cancer	0.000185	0.000416	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ANXA1—esophageal cancer	0.000184	0.000414	CbGpPWpGaD
Methyldopa—COMT—Metabolism—EP300—esophageal cancer	0.00018	0.000405	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP19A1—esophageal cancer	0.00018	0.000404	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SST—esophageal cancer	0.000179	0.000403	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EP300—esophageal cancer	0.000177	0.000397	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GHRL—esophageal cancer	0.000175	0.000393	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH3—esophageal cancer	0.000175	0.000393	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FBXW7—esophageal cancer	0.000172	0.000386	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—esophageal cancer	0.000164	0.000368	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—esophageal cancer	0.000157	0.000354	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH2—esophageal cancer	0.000157	0.000352	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—esophageal cancer	0.00015	0.000337	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR2—esophageal cancer	0.000139	0.000312	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—esophageal cancer	0.000133	0.0003	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SMAD4—esophageal cancer	0.000131	0.000296	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—esophageal cancer	0.000131	0.000294	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—esophageal cancer	0.000126	0.000284	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—esophageal cancer	0.000108	0.000242	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CREBBP—esophageal cancer	0.000105	0.000236	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—esophageal cancer	0.000103	0.000231	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—esophageal cancer	9.69e-05	0.000218	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—esophageal cancer	9.41e-05	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CREBBP—esophageal cancer	8.79e-05	0.000198	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—esophageal cancer	8.64e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—esophageal cancer	8.61e-05	0.000194	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—esophageal cancer	8.25e-05	0.000186	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—esophageal cancer	7.87e-05	0.000177	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—esophageal cancer	7.49e-05	0.000169	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—esophageal cancer	7.36e-05	0.000166	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—EP300—esophageal cancer	7.16e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCND1—esophageal cancer	6.5e-05	0.000146	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—esophageal cancer	6.29e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EP300—esophageal cancer	5.99e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—esophageal cancer	5.29e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—esophageal cancer	5.22e-05	0.000117	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—esophageal cancer	5.1e-05	0.000115	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—esophageal cancer	4.43e-05	9.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—esophageal cancer	4.28e-05	9.63e-05	CbGpPWpGaD
